These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

727 related items for PubMed ID: 31229669

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A, Larcher R, Le Souder C, Djebli N, Khier S.
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [Abstract] [Full Text] [Related]

  • 3. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
    Minichmayr IK, Roberts JA, Frey OR, Roehr AC, Kloft C, Brinkmann A.
    J Antimicrob Chemother; 2018 May 01; 73(5):1330-1339. PubMed ID: 29425283
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
    Idoate Grijalba AI, Aldaz Pastor A, Marquet P, Woillard JB.
    Eur J Clin Pharmacol; 2019 Oct 01; 75(10):1405-1414. PubMed ID: 31338539
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D, Będźkowska A, Ziółkowski H, Jaroszewski J, Borys M, Czuczwar M, Wiczling P.
    Pharmacol Rep; 2020 Jun 01; 72(3):719-729. PubMed ID: 32301057
    [Abstract] [Full Text] [Related]

  • 11. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.
    Morales Junior R, Mizuno T, Paice KM, Pavia KE, Hambrick HR, Tang P, Jones R, Gibson A, Stoneman E, Curry C, Kaplan J, Tang Girdwood S.
    J Antimicrob Chemother; 2024 Oct 01; 79(10):2668-2677. PubMed ID: 39092928
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
    Kim YK, Lee DH, Jeon J, Jang HJ, Kim HK, Jin K, Lim SN, Lee SS, Park BS, Kim YW, Shin JG, Kiem S.
    Clin Ther; 2018 Aug 01; 40(8):1384-1395. PubMed ID: 30093133
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y, Cheng Z, Xie F.
    Antimicrob Agents Chemother; 2022 Sep 20; 66(9):e0082222. PubMed ID: 36005753
    [Abstract] [Full Text] [Related]

  • 17. Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients.
    Liebchen U, Weinelt F, Scharf C, Schroeder I, Paal M, Zoller M, Kloft C, Jung J, Michelet R.
    Antimicrob Agents Chemother; 2022 Feb 15; 66(2):e0183121. PubMed ID: 34871092
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.